In the NTI newsroom we really like to give those in our splendid profession the news, views and opinions as it is and as they are, adapted for our readers. Those who work in restructuring, insolvency and business and don't want to hear a journalist's feckless views on pre-packs and CVAs and 'the 'Bankruptcy' (sic) of companies'.
At NTI we have been back in the lecture room for two weeks and have taken the pulse of students who are sick of the rubbish they have been fed on the news about the state of the nation, the globe and its population. So when we saw this piece in the Financial Times about the preparation of a Covid-19 vaccine last evening we wanted to give it to you, straight; as it is and with no comment.
Enjoy.
The path to a rapid, proven and widely available Coronavirus vaccine will not be straightforward. There are now more than 300 experimental products, according to the World Health Organization: roughly 40 are being tested on humans, and only nine of those have reached the final stage before possible implementation: phase 3 trials. Drug companies will be expected to hit a series of milestones before they are allowed to distribute a Covid-19 vaccine, a move experts say makes it unlikely one will be approved before the US election in November.
Wealthy countries representing just 13 per cent of the world’s population have bought more than half of the leading vaccine candidates’ promised doses, according to Oxfam, the charity. The US Government’s Biomedical Advanced Research and Development Authority is the biggest spender on vaccines, having distributed more than $10 billion in funding for vaccine candidates, either via direct financing or through vaccine procurement agreements.
On a per-capita basis, the UK has built the largest and most diversified vaccine portfolio, according to data from Deutsche Bank, having pre-ordered more than five doses per citizen spread across six leading vaccine candidates. The UK is followed closely by the US, Canada and Japan.
